| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.006 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.084 | 0.06 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.076 | 0.09 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.074 | 0.09 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.061 | 0.2 |